A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Last Updated May 14, 2025
Want to learn how to participate in this trial?
87562761MMY1001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 1 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D[s]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).
CONDITIONS
- Relapsed or Refractory Multiple Myeloma
ELIGIBILITY
Inclusion Criteria:
* Relapsed, refractory multiple myeloma with measurable disease defined as: (a) Serum monoclonal paraprotein (M-protein) level greater than (>)0.5 grams per deciliter (g/dL); or (b) Urine M-protein level >200 milligrams per 24 hours (mg/24 hours); or (c) Light ch
DETAILS
LOCATIONS
Country (2) | City or Province (6) | Status |
Canada | Toronto Princess Margaret Hospital |
RECRUITING
|
Spain | Madrid Hosp Univ Fund Jimenez Diaz |
RECRUITING
|
Spain | Pamplona Clinica Univ. de Navarra |
RECRUITING
|
Spain | Badalona Hosp. Univ. Germans Trias I Pujol |
RECRUITING
|
Spain | Barcelona Hosp Clinic de Barcelona |
RECRUITING
|
Spain | Salamanca Hosp Clinico Univ de Salamanca |
RECRUITING
|
43.70011, -79.4163
40.4165, -3.70256
42.81687, -1.64323
41.45004, 2.24741
41.38879, 2.15899
40.96882, -5.66388
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.